An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

Agnieszka Fiszer1, Marta Olejniczak, Pawel M Switonski

  • 1Laboratory of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland.

BMC Molecular Biology
|March 9, 2012
PubMed
Abstract

Insights

Oligonucleotide strategies show promise for treating polyglutamine (polyQ) diseases by silencing disease-causing genes. Allele-selective approaches, particularly targeting CAG repeats, offer the most potential for effective and universal therapeutic development.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Polyglutamine (polyQ) disorders, including Huntington's disease, are caused by expanded CAG repeats.
  • RNA interference (RNAi) and antisense strategies are being explored as therapeutic agents for these genetic disorders.

Purpose of the Study:

  • To compare the efficacy and allele selectivity of various oligonucleotide-based strategies for silencing genes implicated in polyQ diseases.
  • To evaluate nonallele-selective gene silencing, gene replacement, SNP targeting, and CAG repeat targeting approaches.

Main Methods:

  • Utilized patient-derived cell culture models of Huntington's disease and spinocerebellar ataxias (types 1 and 3).
  • Tested various small interfering RNAs (siRNAs) and antisense reagents.
  • Assessed gene silencing efficiency and allele selectivity based on target binding and RISC-induced cleavage or translational inhibition.

Main Results:

  • SNP-targeting siRNAs demonstrated allele discrimination by exploiting differential base pairing at the cleavage site.
  • MicroRNA-like reagents targeting CAG repeats showed strong allele discrimination by inhibiting translation without significant cleavage.
  • Morpholino analogs exhibited good allele discrimination but faced delivery challenges.

Conclusions:

  • Oligonucleotide strategies offer diverse approaches for polyQ disease therapy, each with unique advantages and drawbacks.
  • Allele-selective RNAi, especially CAG repeat targeting, shows high potential for universality and therapeutic benefit.
  • Gene replacement strategies warrant further investigation as a logical extension of gene silencing approaches.